Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Harvard Bioscience (HBIO) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for Harvard Bioscience (HBIO) over the last 16 years, with Q3 2025 value amounting to -$1.2 million.

  • Harvard Bioscience's Consolidated Net Income rose 7430.24% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$53.8 million, marking a year-over-year decrease of 27876.57%. This contributed to the annual value of -$12.4 million for FY2024, which is 26325.04% down from last year.
  • Per Harvard Bioscience's latest filing, its Consolidated Net Income stood at -$1.2 million for Q3 2025, which was up 7430.24% from -$2.3 million recorded in Q2 2025.
  • Over the past 5 years, Harvard Bioscience's Consolidated Net Income peaked at $2.4 million during Q2 2022, and registered a low of -$50.3 million during Q1 2025.
  • Its 5-year average for Consolidated Net Income is -$4.2 million, with a median of -$1.3 million in 2023.
  • Examining YoY changes over the last 5 years, Harvard Bioscience's Consolidated Net Income showed a top increase of 69048.78% in 2022 and a maximum decrease of 189411.76% in 2022.
  • Over the past 5 years, Harvard Bioscience's Consolidated Net Income (Quarter) stood at $590000.0 in 2021, then plummeted by 466.78% to -$2.2 million in 2022, then increased by 15.99% to -$1.8 million in 2023, then skyrocketed by 102.75% to $50000.0 in 2024, then plummeted by 2568.0% to -$1.2 million in 2025.
  • Its Consolidated Net Income was -$1.2 million in Q3 2025, compared to -$2.3 million in Q2 2025 and -$50.3 million in Q1 2025.